Published in Pediatr Nephrol on December 14, 2013
Seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Hypertension (2003) 63.78
Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies. Lancet (2002) 40.37
Global burden of hypertension: analysis of worldwide data. Lancet (2005) 32.76
The fourth report on the diagnosis, evaluation, and treatment of high blood pressure in children and adolescents. Pediatrics (2004) 31.85
Renal outcomes with telmisartan, ramipril, or both, in people at high vascular risk (the ONTARGET study): a multicentre, randomised, double-blind, controlled trial. Lancet (2008) 13.34
Preventing microalbuminuria in type 2 diabetes. N Engl J Med (2004) 6.41
Strict blood-pressure control and progression of renal failure in children. N Engl J Med (2009) 5.71
Measuring blood pressure for decision making and quality reporting: where and how many measures? Ann Intern Med (2011) 5.31
High blood pressure trends in children and adolescents in national surveys, 1963 to 2002. Circulation (2007) 4.36
Overweight, ethnicity, and the prevalence of hypertension in school-aged children. Pediatrics (2004) 4.18
Trends in blood pressure among children and adolescents. JAMA (2004) 4.03
Effect of home blood pressure telemonitoring and pharmacist management on blood pressure control: a cluster randomized clinical trial. JAMA (2013) 3.55
Essential hypertension predicted by tracking of elevated blood pressure from childhood to adulthood: the Bogalusa Heart Study. Am J Hypertens (1995) 3.07
Adverse effects of combination angiotensin II receptor blockers plus angiotensin-converting enzyme inhibitors for left ventricular dysfunction: a quantitative review of data from randomized clinical trials. Arch Intern Med (2007) 1.95
Aliskiren, a novel orally effective renin inhibitor, provides dose-dependent antihypertensive efficacy and placebo-like tolerability in hypertensive patients. Circulation (2005) 1.89
The renin-angiotensin aldosterone system: pathophysiological role and pharmacologic inhibition. J Manag Care Pharm (2007) 1.76
The preparation, purification, and amino acid sequence of a polypeptide renin substrate. J Exp Med (1957) 1.68
Pharmacokinetics of the oral direct renin inhibitor aliskiren alone and in combination with irbesartan in renal impairment. Clin Pharmacokinet (2007) 1.57
Blood pressure lowering in essential hypertension with an oral renin inhibitor, aliskiren. Hypertension (2003) 1.46
Renal effects of aliskiren compared with and in combination with irbesartan in patients with type 2 diabetes, hypertension, and albuminuria. Diabetes Care (2009) 1.33
Aliskiren, a novel renin inhibitor, is renoprotective in a model of advanced diabetic nephropathy in rats. Diabetologia (2007) 1.31
Determinants of increased angiotensin II levels in severe chronic heart failure patients despite ACE inhibition. Int J Cardiol (2006) 1.20
Renin inhibition with aliskiren: where are we now, and where are we going? J Hypertens (2006) 1.18
Increased chymase-dependent angiotensin II formation in human atherosclerotic aorta. Hypertension (1999) 1.13
The changing face of pediatric hypertension in the era of the childhood obesity epidemic. Pediatr Nephrol (2012) 1.07
Additive effect of ACE inhibition and angiotensin II receptor blockade in type I diabetic patients with diabetic nephropathy. J Am Soc Nephrol (2003) 1.04
The biochemistry of the renin-angiotensin system and its role in hypertension. Am J Med (1976) 0.98
Antihypertensive efficacy, safety, and tolerability of the oral direct renin inhibitor aliskiren in patients with hypertension: a pooled analysis. J Am Soc Hypertens (2010) 0.98
Angiotensin II reactivation and aldosterone escape phenomena in renin-angiotensin-aldosterone system blockade: is oral renin inhibition the solution? Expert Opin Pharmacother (2007) 0.93
Accuracy of blood pressure measurements reported in an electronic medical record during routine primary care visits. J Clin Hypertens (Greenwich) (2011) 0.92
Aliskiren exhibits similar pharmacokinetics in healthy volunteers and patients with type 2 diabetes mellitus. Clin Pharmacokinet (2006) 0.89
Pharmacologic interruption of the renin-angiotensin system and the kidney: differential responses to angiotensin-converting enzyme and renin inhibition. J Am Soc Nephrol (1999) 0.89
The renin-angiotensin-aldosterone system in 2011: role in hypertension and chronic kidney disease. Pediatr Nephrol (2011) 0.89
Aliskiren prevents and ameliorates metabolic syndrome in fructose-fed rats. Arch Med Sci (2011) 0.88
Blood pressure in children and target-organ damage later in life. Pediatr Nephrol (2009) 0.88
Chronic renin inhibition with aliskiren improves glucose tolerance, insulin sensitivity, and skeletal muscle glucose transport activity in obese Zucker rats. Am J Physiol Regul Integr Comp Physiol (2011) 0.86
ACE inhibitors, angiotensin receptor blockers and direct renin inhibitors in combination: a review of their role after the ONTARGET trial. Curr Med Res Opin (2009) 0.85
Additive antiproteinuric effect of ACE inhibitor and losartan in IgA nephropathy. Pediatr Nephrol (2002) 0.85
Aldosterone blockade in chronic kidney disease: can it improve outcome? Curr Opin Nephrol Hypertens (2010) 0.85
Direct renin inhibitors: the dawn of a new era, or just a variation on a theme? Nephrol Dial Transplant (2007) 0.82
Pharmacokinetics, safety, and tolerability of the oral Renin inhibitor aliskiren in patients with hepatic impairment. J Clin Pharmacol (2007) 0.81
Pharmacokinetics, safety profile, and efficacy of aliskiren in pediatric patients with hypertension. Clin Pediatr (Phila) (2013) 0.81
An issue of dependence: implications from the Aliskiren in the Evaluation of Proteinuria in Diabetes (AVOID) trial. J Clin Hypertens (Greenwich) (2009) 0.80
Not ready for prime time: aliskiren for treatment of hypertension or proteinuria in children. Pediatr Nephrol (2010) 0.79
Efficacy, safety and tolerability of aliskiren, a direct renin inhibitor, in women with hypertension: a pooled analysis of eight studies. J Hum Hypertens (2010) 0.79
[Management of high blood pressure in children and adolescents: Recommendations of the European Society of hypertension]. An Pediatr (Barc) (2010) 0.78
Reducing cardiorenal risk through combination therapy with a direct renin inhibitor. J Clin Hypertens (Greenwich) (2011) 0.78
Pediatric ambulatory blood pressure monitoring: diagnosis of hypertension. Pediatr Nephrol (2013) 0.77
Aliskiren, the first in a new class of direct renin inhibitors for hypertension: present and future perspectives. Expert Opin Pharmacother (2007) 0.76
Home blood pressure monitoring: take it to the bank. JAMA (2013) 0.76
Are we ready to use aliskiren in children? Pediatr Nephrol (2010) 0.76
ACP Journal Club. Aliskiren increased adverse events in patients with diabetes and kidney disease who were receiving ACE inhibitors or ARBs. Ann Intern Med (2013) 0.76
Increased prevalence of elevated blood pressures in HIV-infected children, adolescents and young adults. Pediatr Infect Dis J (2015) 1.40
Blood pressure and school performance. Psychosom Med (2014) 1.06
Pharmacologic treatment of chronic pediatric hypertension. Paediatr Drugs (2005) 1.04
Body mass index in primary and secondary pediatric hypertension. Pediatr Nephrol (2004) 0.95
Abnormal left ventricular mass and aortic distensibility in pediatric dialysis patients. Pediatr Nephrol (2004) 0.88
A multicenter study of the pharmacokinetics of lisinopril in pediatric patients with hypertension. Pediatr Nephrol (2007) 0.85
Pharmacokinetics of valsartan in pediatric and adolescent subjects with hypertension. J Clin Pharmacol (2009) 0.81
Significance of heritability in primary and secondary pediatric hypertension. Am J Hypertens (2005) 0.80
A multicenter study of neurocognition in children with hypertension: methods, challenges, and solutions. J Am Soc Hypertens (2013) 0.79
Effectiveness of pretreatment in decreasing adverse events associated with pamidronate in children and adolescents. Pharmacotherapy (2004) 0.77
Management of nephrotic syndrome in children. Pharmacotherapy (2003) 0.75
In Reply: Increased Prevalence of Elevated Blood Pressures in HIV-infected Children, Adolescents, and Young Adults. Pediatr Infect Dis J (2016) 0.75
When listening for hoofbeats, sometimes there are zebras-an interesting case of a teenager with edema and high blood pressure: Answers. Pediatr Nephrol (2014) 0.75
When listening for hoofbeats, sometimes there are zebras--an interesting case of a teenager with edema and high blood pressure. Pediatr Nephrol (2014) 0.75
Treatment: special conditions: assessing blood pressure in children and adolescents. J Am Soc Hypertens (2014) 0.75